Biopharma Quarter: Key Trends and Events of the Fourth Quarter of 2008
Decision Resources
March 30, 2009 48 Pages - SKU: DECR2219107
|
|
Introduction
2008 came to a close amid political transition in the world's largest pharmaceutical market and economic upheaval
in all of the world's markets. Our review of key events that occurred in the fourth quarter and prominent
trends at play in that time frame refl ects that backdrop and fi nds that companies in the biopharma industry have
an opportunity to move outside of traditional models to tap new opportunities-and some are making big strides
in doing so.
Get the Answers You Need to Shape Your Strategy
- There's a new administration in Washington. What are the prospects for expanded care? What are the
targets of cost-containment? How do administration policies present opportunity for the biopharma
industry?
- Healthcare is generally regarded as a stable industry in a down economy, but biopharma is feeling the effects
of the global recession. How is access to healthcare changing? How is access to funding changing? How
are biopharma companies affected, and how are they adjusting their general business and dealmaking
strategies?
- Spectrum has advised the industry to adapt to inevitable changes in the industry. What are the promising
strategies and new directions for biopharma companies? How can companies turn challenges into
opportunities?
Scope
- Events: political change in the United States and United Kingdom, effects of the economy on the
industry's fortunes, new moves on the lifestyle drugs landscape, new competitive considerations in
the emerging market of China.
- Dealmaking: deal type, deal value, deal focus, most active companies, therapeutic areas.
- Generics: related deals, biosimilars, Big Pharma participation, early competition for clopidogrel,
opening of the Japanese market.
- Strategy: the varied affect of the economy on biotechs versus Big Pharma; new imperatives in the
response to the economy; new scrutiny of Big Pharma responses to generic competition.
- Expert commentaries: generics industry perspectives, strategy perspectives, U.K. policy news perspective,
Japanese biosimilar industry news perspective, Chinese intellectual property news perspective,
Lilly's fourth-quarter dealmaking strategy perspective.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Events Perspective
- On the Political Front: Focus on Themes of the U.S. Elections
- Expanded Access
- Cost Containment
- Cost-Effective, Quality Care
- Support for Innovation
- On the Economic Front: Quantifying the Impact of the Recession
- On the Approvals Front: Latisse Became the Latest Entry in the Lifestyle Drugs Category
- On the International Front: Focus on Chinese Pharma Manufacturing
- Deals Perspective
- Deals by Company
- Deal Type
- Acquisitions
- Collaborations and Licensing
- Deals by Therapeutic Area—Oncology Focus
- Product Deals
- Generics Perspective: Pro-Generics Governments Boost the Generics Industry
- Increased Big Pharma Involvement in Generics
- U.S. Biosimilars Guidelines Delayed—For Now
- FDA Clampdowns—A Reaction to the Heparin Fiasco?
- Generic Plavix Reaches European Market Early Through a Legal Loophole
- Japanese Generics Market Starts to Open
- Strategy Perspective: Global Economic Crisis Is a Prelude to Greater Challenges for Biopharma
- Biotech Sector: Cash Crunch, Company Crashes, and a Cull
- Pharma Sector: Missing a Master Plan for Necessary Transformation
- Pending Challenges for the Industry
- Tables
- 1. Targets of Select Key Cost-Containment Measures in the Major Markets
- 2. Select PGx-Based Diagnostic Tests
- 3. Select Companies Working on Stem Cell Technologies and Therapies
- 4. Select Drugs in Development for Autism
- 5. Worldwide 2007 Sales of Select “Lifestyle” Drugs
- 6. Leading Domestic and Multinational Pharmaceutical Companies in China
- 7. Key Fourth-Quarter Findings of Decision Resources’ Emerging Markets Research and Analysis
- 8. Company Dealmaking Activity, Q4 2008
- 9. Select Big Pharma Acquisitions, Q4 2008
- 10. Select Big Pharma Collaborations, Q4 2008
- 11. Select Big Pharma Licensing, Q4 2008
- 12. Select Fourth Quarter Oncology Deals, 2008
- 13. Biosimilar Agents in the European Union and the United States
- 14. Generic Expansion into Japan, Q4 2008
- Figures
- 1. Qualitative Assessment of Implications of U.S. Healthcare Reform for Biopharma
- 2. Healthcare Statistics in the United States Versus Select Nations That Provide Universal Health Insurance
- 3. Year in Review: Market Sector Stock Indices
- 4. Impact of Cost of Care on Access to Care in the United States Versus Select Nations That Provide Universal Health Insurance
- 5. Fourth-Quarter 2008 U.S. Drug Approval Tallies and Highlights
- 6. Volume of Pharma and Biotech Deals, 2006-2008
- 7. Pharma and Biotech Deals Valued Over $100MM, 2006-2008
- 8. Largest Deals of Q4 2008, by Value
- 9. Therapeutic Area Focus of Deals, Q4 2008
- 10. Product Dealmaking Activities Between Companies, Q4 2008
- 11. Phase of Development of 54 Inlicensed Products, Q4 2008
- 12. Categories of Inlicensed Products, Q4 2008
- 13. Most Important Issues and Labeling Requirements for Regulatory Authorities
- 14. Extensive Layoffs in the Pharmaceutical Industry, 2007-2008
- Expert Commentaries
- Prospects for Improved Access to Innovative Medicines in the United Kingdom
- Outlook for Foreign Pharma in the Face of China’s New Patent Law
- Gilding Lilly? A Look at the ImClone Acquisition
- Biosimilars in Japan: The Threat Level Is Low
Share this report
Other tasks Related Markets Biopharmaceuticals Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
